A randomized, placebo-controlled first-in-human study of oral TQS-168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect.

PGC‐1α gene expression The change from baseline in mean PGC‐1α gene expression was slightly higher following administration of 90, 120, or 300 mg/day TQS‐168 compared to placebo (Figure 3 ), however, the differences from placebo did not reach statistical significance.

also in 111,027 other papers